Clinical Trial Update: Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI [Phase 2, Phase 3]

View source ↗

Summary

Terminated extension study (Phase 2/Phase 3) evaluating CDZ173 in Activated PI3K delta syndrome (APDS) and PASLI disease; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Activated Pi3k-delta Syndrome
• Pasli Disease

Drugs mentioned

• CDZ173 (CDZ173)

Snippet

Sponsor: Pharming Technologies B.V. | Conditions: Activated PI3Kdelta Syndrome (APDS); PASLI Disease | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2026-03-30